Antrenyl is developed by Novartis.

What development phase is Antrenyl in?

Antrenyl is FDA-approved (marketed).

What is the generic name of Antrenyl?

OXYPHENONIUM is the generic (nonproprietary) name of Antrenyl.

Last reviewed 2026-04-20 · How we verify

Antrenyl (OXYPHENONIUM)

Novartis · FDA-approved approved Small molecule Quality 10/100

At a glance

Generic name	OXYPHENONIUM
Sponsor	Novartis
Drug class	oxyphenonium
Target	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Methadone to Treat Painful Chemotherapy Induced Peripheral Neuropathy (PHASE2,PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Antrenyl CI brief — competitive landscape report
Antrenyl updates RSS · CI watch RSS
Novartis portfolio CI